RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma

British Journal of Haematology

Volumn 156, Issue 2, 2012, Pages 234-244

  Corazzelli, Gaetano ^a   Frigeri, Ferdinando ^a   Russo, Filippo ^a   Frairia, Chiara ^b   Arcamone, Manuela ^a   Esposito, Gennaro ^a   De Chiara, Annarosaria ^a   Morelli, Emanuela ^a   Capobianco, Gaetana ^a   Becchimanzi, Cristina ^a   Volzone, Francesco ^a   Saggese, Mariangela ^a   Marcacci, Giampaolo ^a   De Filippi, Rosaria ^a,c   Vitolo, Umberto ^b   Pinto, Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Burkitt lymphoma; CNS prophylaxis; Liposomal cytarabine; Magrath regimen; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLURRED VISION; BRADYCARDIA; BURKITT LYMPHOMA; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HEADACHE; HUMAN; LOW BACK PAIN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REMISSION; SOMNOLENCE; TREATMENT FAILURE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, SPINAL; LIPOSOMES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED;

EID: 84155186346     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08947.x     Document Type: Article

References (50)

1. Barnes, J.A., Lacasce, A., Feng, Y., Toomey, C., Neuberg, D., Hochberg, E.P. & Abramson, J.S. (2009) Rituximab added to CODOX-M/IVAC has no clear benefit compared to CODOX-M/IVAC alone in adult patients with Burkitt Lymphoma. Blood, 114, Abstract 1667.
2. Barnes, J.A., Lacasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, J.S., Hochberg, E.P. & Abramson, J.S. (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol, 22, 1859-1864.
3. Bernstein, J.I., Coleman, C.N., Strickler, J.G., Dorfman, R.F. & Rosenberg, S.A. (1986) Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). Journal of Clinical Oncology, 4, 847-858.
4. Bleyer, W.A. (1999) Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium. Clinical Cancer Research, 5, 3349-3351.
5. Blum, K.A., Lozanski, G. & Byrd, J.C. (2004) Adult Burkitt leukemia and lymphoma. Blood, 104, 3009-3020.
6. Chamberlain, M.C. & Kormanik, P.A. (1996) Prognostic significance of 11-DTPA CSF flow studies in leptomeningeal metastases. Neurology, 46, 1674-1677.
7. Cole, B.F., Glantz, M.J., Jaeckle, K.A., Chamberlain, M.C. & Mackowiak, J.I. (2003) Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer, 97, 3053-3060.
8. Corazzelli, G., Russo, F., Capobianco, G., Marcacci, G., Della Cioppa, P. & Pinto, A. (2006) Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Annals of Oncology, 17(Suppl 4), iv18-24.
9. Dave, S.S., Fu, K., Wright, G.W., Lam, L.T., Kluin, P., Boerma, E.J., Greiner, T.C., Weisenburger, D.D., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Delabie, J., Rimsza, L.M., Braziel, R.M., Grogan, T.M., Campo, E., Jaffe, E.S., Dave, B.J., Sanger, W., Bast, M., Vose, J.M., Armitage, J.O., Connors, J.M., Smeland, E.B., Kvaloy, S., Holte, H., Fisher, R.I., Miller, T.P., Montserrat, E., Wilson, W.H., Bahl, M., Zhao, H., Yang, L., Powell, J., Simon, R., Chan, W.C. & Staudt, L.M. (2006) Molecular diagnosis of Burkitt's lymphoma. New England Journal of Medicine, 354, 2431-2442.
10. DeAngelis, L.M. (1998) Current diagnosis and treatment of leptomeningeal metastasis. Journal of Neuro-Oncology, 38, 245-252.
11. Divine, M., Casassus, P., Koscielny, S., Bosq, J., Sebban, C., Le Maignan, C., Stamattoulas, A., Dupriez, B., Raphael, M., Pico, J.L. & Ribrag, V. (2005) Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Annals of Oncology, 16, 1928-1935.
12. Dunleavy, K., Pittaluga, S., Wayne, A.S., Shovlin, J.L., Johnson, J.L., Little, R., Steinberg, S., Cheson, B.D., Hsi, E., Jaffe, E.S. & Wilson, W.H. (2011) Myc+ aggressive B-cell lymphomas: novel therapy of untreated Burkitt Lymphoma and Myc+ Diffuse Large B-cell Lymphoma with DA-EPOCH-R. Annals of Oncology, 22, iv107.
13. Fleischhack, G., Jaehde, U. & Bode, U. (2005) Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clinical Pharmacokinetics, 44, 1-31.
14. Franco, R., Camacho, F.I., Caleo, A., Staibano, S., Bifano, D., De Renzo, A., Tranfa, F., De Chiara, A., Botti, G., Merola, R., Diez, A., Bonavolonta, G., De Rosa, G. & Piris, M.A. (2006) Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Modern Pathology, 19, 1055-1067.
15. Glantz, M.J., LaFollette, S., Jaeckle, K.A., Shapiro, W., Swinnen, L., Rozental, J.R., Phuphanich, S., Rogers, L.R., Gutheil, J.C., Batchelor, T., Lyter, D., Chamberlain, M., Maria, B.L., Schiffer, C., Bashir, R., Thomas, D., Cowens, W. & Howell, S.B. (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. Journal of Clinical Oncology, 17, 3110-3116.
16. Hill, Q.A. & Owen, R.G. (2006) CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Reviews, 20, 319-332.
17. Hoelzer, D. (2008) Recent results in the treatment of Burkitt lymphomas [abstract]. Annals of Oncology, 19(Suppl 4), iv83.
18. Hoelzer, D. (2009) Update on burkitt lymphoma and leukemia. Clinical Advances in Hematology and Oncology, 7, 728-729.
19. Hoelzer, D., Ludwig, W.D., Thiel, E., Gassmann, W., Loffler, H., Fonatsch, C., Rieder, H., Heil, G., Heinze, B., Arnold, R., Hossfeld, D., Buchner, T., Koch, P., Freund, M., Hiddemann, W., Maschmeyer, G., Heyll, A., Aul, C., Faak, T., Kuse, R., Ittel, T.H., Gramatzki, M., Diedrich, H., Kolbe, K., Fuhr, H.G., Fischer, K., Schadeck-Gressel, C., Weiss, A., Strohscheer, I., Metzner, B., Fabry, U., Gokbuget, N., Volkers, B., Messerer, D. & Uberla, K. (1996) Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood, 87, 495-508.
20. Jabbour, E., Thomas, D., Cortes, J., Kantarjian, H.M. & O'Brien, S. (2005) Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer, 116, 2290-2300.
21. Jabbour, E., O'Brien, S., Kantarjian, H., Garcia-Manero, G., Ferrajoli, A., Ravandi, F., Cabanillas, M. & Thomas, D.A. (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood, 109, 3214-3218.
22. Jaffe, E., Harris, N.L., Stein, H. & Vardiman J.W. (Eds) (2001) Burkitt lymphoma. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. pp. 181-183. IARC Press, Lyon.
23. Kasamon, Y.L. & Swinnen, L.J. (2004) Treatment advances in adult Burkitt lymphoma and leukemia. Current Opinion in Oncology, 16, 429-435.
24. Kelly, J.L., Toothaker, S.R., Ciminello, L., Hoelzer, D., Holte, H., LaCasce, A.S., Mead, G., Thomas, D., Van Imhoff, G.W., Kahl, B.S., Cheson, B.D., Magrath, I.T., Fisher, R.I. & Friedberg, J.W. (2009) Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clinical Lymphoma, Myeloma, 9, 307-310.
25. Kim, S., Chatelut, E., Kim, J.C., Howell, S.B., Cates, C., Kormanik, P.A. & Chamberlain, M.C. (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. Journal of Clinical Oncology, 11, 2186-2193.
26. Lacasce, A., Howard, O., Lib, S., Fisher, D., Weng, A., Neuberg, D. & Shipp, M. (2004) Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leukaemia & Lymphoma, 45, 761-767.
27. Leoncini, L., Deisol, G., Gascoyne, R.D. & al., E. (2005) Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haemopathology. Histopathology, 46, 241-255.
28. Magrath, I.T., Janus, C., Edwards, B.K., Spiegel, R., Jaffe, E.S., Berard, C.W., Miliauskas, J., Morris, K. & Barnwell, R. (1984) An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood, 63, 1102-1111.
29. Magrath, I., Adde, M., Shad, A., Venzon, D., Seibel, N., Gootenberg, J., Neely, J., Arndt, C., Nieder, M., Jaffe, E., Wittes, R.A. & Horak, I.D. (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology, 14, 925-934.
30. Maruyama, D., Watanabe, T., Maeshima, A.M., Nomoto, J., Taniguchi, H., Azuma, T., Mori, M., Munakata, W., Kim, S.W., Kobayashi, Y., Matsuno, Y. & Tobinai, K. (2010) Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. International Journal of Hematology, 92, 732-743.
31. Mead, G.M., Sydes, M.R., Walewski, J., Grigg, A., Hatton, C.S., Pescosta, N., Guarnaccia, C., Lewis, M.S., McKendrick, J., Stenning, S.P. & Wright, D. (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology, 13, 1264-1274.
32. Mead, G.M., Barrans, S.L., Qian, W., Walewski, J., Radford, J.A., Wolf, M., Clawson, S.M., Stenning, S.P., Yule, C.L. & Jack, A.S. (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood, 112, 2248-2260.
33. Mohamedbhai, S.G., Sibson, K., Marafioti, T., Kayani, I., Lowry, L., Goldstone, A.H., Linch, D.C. & Ardeshna, K.M. (2011) Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. British Journal of Haematology, 152, 175-181.
34. Muldoon, L.L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q.R., Hall, W.A., Hynynen, K., Senter, P.D., Peereboom, D.M. & Neuwelt, E.A. (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. Journal of Clinical Oncology, 25, 2295-2305.
35. Nomura, Y., Karube, K., Suzuki, R., Ying, G., Takeshita, M., Hirose, S., Nakamura, S., Yoshino, T., Kikuchi, M. & Ohshima, K. (2008) High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients. Cancer Science, 99, 246-252.
36. Oriol, A., Ribera, J.M., Bergua, J., Gimenez Mesa, E., Grande, C., Esteve, J., Brunet, S., Moreno, M.J., Escoda, L., Hernandez-Rivas, J.M. & Hoelzer, D. (2008) High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer, 113, 117-125.
37. Perkins, A.S. & Friedberg, J.W. (2008) Burkitt lymphoma in adults. Hematology the Education Program of the American Society of Hematology, 1, 341-348.
38. Rizzieri, D.A., Johnson, J.L., Niedzwiecki, D., Lee, E.J., Vardiman, J.W., Powell, B.L., Barcos, M., Bloomfield, C.D., Schiffer, C.A., Peterson, B.A., Canellos, G.P. & Larson, R.A. (2004) Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer, 100, 1438-1448.
39. Rizzieri, D.A., Johnson, J.L., Byrd, J.C., Lozanski, G., Powell, J., Shea, T.C., Nattom, S., Hoke, E., Chessin, L.N. & Larson, R. (2010) Efficacy and toxicity of Rituximab and brief duration, high intensity chemotherapy with Filgrastim support in Burkitt or Burkitt/like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002. Blood, 116, Abstract 858.
40. Rueda Dominguez, A., Olmos Hidalgo, D., Viciana Garrido, R. & Torres Sanchez, E. (2005) Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clinical and Translational Oncology, 7, 232-238.
41. Salaverria, I. & Siebert, R. (2011) The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. Journal of Clinical Oncology, 29, 1835-1843.
42. Sariban, E., Edwards, B., Janus, C. & Magrath, I. (1983) Central nervous system involvement in American Burkitt's lymphoma. Journal of Clinical Oncology, 1, 677-681.
43. Shapiro, W.R., Young, D.F. & Mehta, B.M. (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. New England Journal of Medicine, 293, 161-166.
44. Smeland, S., Blystad, A.K., Kvaloy, S.O., Ikonomou, I.M., Delabie, J., Kvalheim, G., Hammerstrom, J., Lauritzsen, G.F. & Holte, H. (2004) Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Annals of Oncology, 15, 1072-1078.
45. Spina, M., Chimienti, E., Martellotta, F., Vaccher, E., Berretta, M., Zanet, E., Lleshi, A., Canzonieri, V., Bulian, P. & Tirelli, U. (2010) Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer, 116, 1495-1501.
46. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J & Vardiman JW. (Eds) (2008) Burkitt lymphoma. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. pp. 262-263. IARC Press, Lyon.
47. Thomas, D.A., Cortes, J., O'Brien, S., Pierce, S., Faderl, S., Albitar, M., Hagemeister, F.B., Cabanillas, F.F., Murphy, S., Keating, M.J. & Kantarjian, H. (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 17, 2461-2470.
48. Thomas, D.A., Faderl, S., O'Brien, S., Bueso-Ramos, C., Cortes, J., Garcia-Manero, G., Giles, F.J., Verstovsek, S., Wierda, W.G., Pierce, S.A., Shan, J., Brandt, M., Hagemeister, F.B., Keating, M.J., Cabanillas, F. & Kantarjian, H. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 106, 1569-1580.
49. Wasterlid, T., Jonsson, B., Hagberg, H. & Jerkeman, M. (2011) Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leukaemia & Lymphoma, 52, 2090-2096.
50. Zimm, S., Collins, J.M., Miser, J., Chatterji, D. & Poplack, D.G. (1984) Cytosine arabinoside cerebrospinal fluid kinetics. Clinical Pharmacology and Therapeutics, 35, 826-830.